Makes scientific and analytical instruments, including mass spectrometers, plus medical imaging equipment.
Makes scientific and analytical instruments, including mass spectrometers, plus medical imaging equipment.
Sells analytical instruments to labs and then supplies recurring service and consumables, such as columns and replacement parts, for the installed base. Separate businesses cover x-ray imaging for hospitals, aircraft equipment and industrial machinery. A large share of sales comes from outside Japan.
In one line: A smaller Agilent/Thermo Fisher.
Moat: narrow (process know-how, installed base). Precision analytical-instrument expertise and installed base drive recurring service/consumables.
Headquarters: Kyoto, Japan · Founded: 1875 · Employees: 14,649
Size Shimadzu (7701.T) is a Japan Health Care company (Medical Specialties) with a market value of $8.14B, the 169th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,353 on 18 Nov 2026.
Performance Over six months the shares gained 24.2%, against +27.8% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 7.8% over the last twelve months (peer median +3.4%); the operating margin is 13.6% (peer median 18.0%).
Valuation It trades at 21.0× forward earnings against a peer median of 20.3× (11th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.4 points above its cost of capital (7.4% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥586B | ¥561B | ¥539B | ¥512B | ¥482B |
| Revenue growth | — | +4% | +5% | +6% | — |
| Gross profit | ¥266B | ¥250B | ¥234B | ¥221B | ¥201B |
| EBITDA | ¥101B | ¥95.0B | ¥92.4B | ¥91.9B | ¥86.1B |
| Net income | ¥65.1B | ¥60.5B | ¥53.8B | ¥57.0B | ¥52.0B |
| Free cash flow | n/a | ¥39.7B | ¥36.9B | ¥14.6B | ¥31.5B |
| Capital expenditure | n/a | ¥14.9B | ¥15.1B | ¥15.5B | ¥16.8B |
| Total debt | ¥121B | ¥10.5B | ¥11.7B | ¥11.9B | ¥11.3B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shimadzu 7701.T | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Agilent Technologies A | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% |
| Sysmex 6869.T | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7701.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.1% | +9.4% | 5th lowest of 21 |
| 6-month return | +24.2% | +27.8% | 9th lowest of 21 |
| Distance from 52-week high | -7.6% | -8.2% | 10th highest of 21 |
| Revenue growth (TTM) | +7.8% | +3.4% | 8th highest of 21 |
| Operating margin | 13.6% | 18.0% | 8th lowest of 21 |
| Forward P/E | 21.0× | 20.3× | 11th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 8.3% | 10.6% | 7th least demanding of 20 |
| Growth delivered (Del g) | +7.3% | +10.3% | 7th lowest of 20 |
| Hurdle (Req g minus delivered) | +0.9 pp | +1.8 pp | 10th least demanding of 20 |
| ROIC minus cost of capital | +2.4 pp | +2.8 pp | 9th lowest of 21 |
| EV / EBITDA | 12.7× | 14.5× | 6th cheapest of 19 |
| Net debt / EBITDA | -0.1× | 1.1× | 6th least indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shimadzu 7701.T | Japan | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% | +7.3% |
| Sysmex 6869.T | Japan | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% | +10.4% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% | +15.7% |
| Getinge GETI-B.ST | Sweden | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% | +3.2% |
| Bausch + Lomb BLCO.TO | Canada | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% | +10.0% |
| Asahi Intecc 7747.T | Japan | $7.09B | +24% | +23% | 32% | 29.7× | 15.1% | +18.8% |
| Globus Medical GMED | United States | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% | +30.1% |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Ypsomed YPSN.SW | Switzerland | $6.83B | +27% | -13% | 30% | 31.7× | n/a | n/a |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |
| ConvaTec CTEC.L | United Kingdom | $6.78B | +37% | +2% | 16% | 17.7× | 17.2% | +4.6% |
| Cochlear COH.AX | Australia | $6.72B | +58% | -1% | 13% | 29.1× | 23.9% | +9.3% |
| Lantheus LNTH | United States | $6.67B | +6% | +2% | 19% | 15.5× | 0.4% | +35.3% |
| Bio-Rad Laboratories BIO | United States | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% | +0.3% |
| Teleflex TFX | United States | $6.58B | +23% | -29% | 12% | 16.7× | 16.5% | -4.7% |
| Qiagen QGEN | United States | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% | +2.2% |
| Demant A/S DEMANT.CO | Denmark | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% | +9.8% |
| Avantor AVTR | United States | $10.4B | +95% | +1% | 8% | 17.5× | 16.4% | +0.5% |
| APT Medical 688617.SS | China | $6.06B | +23% | +28% | 37% | 38.6× | 9.0% | +40.1% |
| Cooper Companies (The) COO | United States | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% | +11.0% |
| Align Technology ALGN | United States | $11.6B | 0% | +4% | 19% | 13.8× | 13.1% | +10.3% |